Ed Esplin: Therapeutic applications of germline testing for cancer predisposition genes in Asia in the real world

Ed Esplin, Clinical Geneticist at Invitae, shared a post on LinkedIn:

“1/3 of cancer patients with genetic testing in an Asian tertiary centre carried a germline PGV.
~75% of advanced cancer patients with actionable PGVs received corresponding targeted therapy.”